US 7,320,791 B2
Monoclonal antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
Steve Roffler, Taipei (Taiwan); Tian-Lu Cheng, Chang Hua (Taiwan); and Pin-Yi Wu, Taipei (Taiwan)
Assigned to Academia Sinica, Taipei (Taiwan)
Filed on Jul. 15, 2003, as Appl. No. 10/620,091.
Application 10/620091 is a division of application No. 09/810379, filed on Mar. 16, 2001, granted, now 6,617,118.
Application 09/810379 is a division of application No. 09/520225, filed on Mar. 07, 2000, granted, now 6,596,849.
Claims priority of provisional application 60/136522, filed on May 28, 1999.
Prior Publication US 2004/0014156 A1, Jan. 22, 2004
Int. Cl. A61K 39/00 (2006.01)
U.S. Cl. 424—133.1  [424/138.1; 424/141.1; 424/155.1; 424/179.1; 424/180.1] 15 Claims
 
1. A method of accelerating the clearance of a polyethylene glycol-containing compound from the circulating blood of a patient to whom the polyethylene glycol-containing compound was previously administered, comprising the step of administering to the patient a pharmaceutical composition comprising an anti-polyethylene glycol monoclonal antibody, wherein the antibody is obtained via immunizing a mouse with an RH1-βG-PEG conjugate, and the polyethylene glycol-containing compound comprises B72.3-βG-PEG or H25-βG-PEG.